Prurigo Nodularis (PN) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Prurigo Nodularis (PN) Market Outlook

Thelansis's "Prurigo Nodularis (PN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prurigo Nodularis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prurigo Nodularis (PN) Overview

Prurigo nodularis is a chronic, intensely itchy skin condition driven by a self-perpetuating cycle of itching and scratching that produces hardened, persistent nodules across the skin and carries a significant burden on sleep and daily quality of life. For years, treatment options were limited to off-label use of topical agents, phototherapy, and various neuromodulating or immunosuppressive medications that often provided incomplete relief, reflecting how poorly understood the underlying biology was for a long time. That changed with growing recognition that the disease stems from a specific interaction between the immune system and the nervous system, which paved the way for targeted biologic therapies, with two now approved that interrupt this itch-driving pathway at different points, one addressing a broader upstream inflammatory signal and the other targeting a nerve-specific itch mediator more directly. Because these two options differ meaningfully in how quickly they relieve itch versus how fully they clear visible nodules over time, treatment selection increasingly considers which symptom matters most to an individual patient.

Key Highlights

• In Germany, the prevalent Prurigo Nodularis (PN) population is projected to increase from 127,122 in 2025 to 129,438 by 2035.
• Prurigo Nodularis is a chronic inflammatory skin disease characterized by severe pruritus and nodular skin lesions.
• Persistent itching and recurrent disease significantly impair patients' quality of life.
• Significant unmet need remains for therapies that provide sustained itch relief and long-term disease control.

Market Overview

• The Germany Prurigo Nodularis market is projected to grow from $45M in 2025 to $95M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologic therapies
• Improved diagnosis and growing disease awareness
• Future growth will depend on therapies capable of delivering durable symptom control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Trevi Therapeutics
• Incyte Corporation
• Sanofi
• Amgen
• Beijing InnoCare Pharma Tech Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Genentech, Inc.